ライフサイエンスコーパス: albendazole

1 integrated treatment (both praziquantel and albendazole).

2 es for praziquantel and two times higher for albendazole.

3 All patients received albendazole.

4 errupted, rather than continuous, courses of albendazole.

5 Surviving recipients received albendazole.

6 solubilize the insoluble benzimidazole drug albendazole.

7 in all six rounds of mass administration of albendazole.

8 The cure rate with albendazole (2.6%) and the egg-reduction rate with alben

9 g per treatment) against schistosomiasis and albendazole (400 mg per treatment) against soil-transmit

10 habitants aged 2 years or older were offered albendazole (400 mg) every 6 months.

11 azole (2.6%) and the egg-reduction rate with albendazole (45.0%; 95% CI, 32.0 to 56.4) were significa

12 plied to different milk samples, residues of albendazole (49mugkg(-1)), sulfamethazine (<LOQ) and meb

13 r intestinal parasites with a single dose of albendazole (600 mg), administered overseas before depar

14 dentified a synergy between the anthelmintic albendazole (ABZ) and drugs depleting the filarial endos

15 bral Taenia solium cysticercosis with either albendazole (ABZ) or praziquantel (PZQ) is suboptimal.

16 per kilogram of body weight, plus 400 mg of albendazole, administered on consecutive days; oxantel p

17 of coinfected children with praziquantel and albendazole affected schistosome- and hookworm-specific

18 thylcarbamazine (DEC), ivermectin (IVM), and albendazole (ALB) for LF are unknown.

19 rected treatment with praziquantel (PZQ) and albendazole (ALB) was analyzed in 17 villages of Mayuge

20 1.4%), and whipworm (86.8% to 59.5%), while albendazole alone significantly reduced prevalence of ho

21 her three groups (20 [69%] placebo, 22 [76%] albendazole alone, 17 [61%] ivermectin alone remained po

22 per 20 microL blood among those who received albendazole alone; and from 13.7 to 0.3 per 20 microL bl

23 Albendazole, an oral drug currently used to treat parasi

24 locks of 100, we assigned patients to 440 mg albendazole and 40 mg/kg praziquantel (n=628), 440 mg al

25 le and 40 mg/kg praziquantel (n=628), 440 mg albendazole and a praziquantel-matching placebo (n=625),

26 ubjects, who were assigned randomly into the albendazole and placebo arms, respectively.

27 ed study of the concurrent administration of albendazole and praziquantel was conducted in>1500 child

28 ed for helminths, treated presumptively with albendazole and selectively with praziquantel, and monit

29 The patient was treated with albendazole and topical fumagillin and responded rapidly

30 either 4 repeated doses or a single dose of albendazole and were followed up during 13 months to ass

31 benzimidazole anthelmintics, mebendazole and albendazole, are commonly used to remove these infection

32 5 days of azithromycin, and a single dose of albendazole, as compared with standard prophylaxis (trim

33 oate at a single dose of 20 mg per kilogram; albendazole at a single dose of 400 mg; or mebendazole a

34 Two extraction strategies for albendazole, chloramphenicol, trimethoprim, enrofloxacin

35 d those who were treated with ivermectin and albendazole [corrected].

36 Albendazole efficacy was good, but 19 of 48 treated pati

37 1:1) eligible participants to either empiric albendazole every 3 months plus praziquantel annually (t

38 atment with metronidazole, nitazoxanide, and albendazole failed to eradicate the infection.

39 ass drug administration with ivermectin plus albendazole for lymphatic filariasis cannot be applied i

40 tion of praziquantel for schistosomiasis and albendazole for soil-transmitted helminths.

41 ted with integrated MDA (of praziquantel and albendazole) for schistosomiasis and soil-transmitted he

42 s significantly lower in the ivermectin plus albendazole group (four [17%]), but there were no signif

43 nd geometric mean titer were observed in the albendazole group in subjects with non-O ABO blood group

44 Whereas albendazole had no effect on IR (estimated treatment eff

45 regimen (ivermectin, diethylcarbamazine, and albendazole) has been shown to clear the transmissible s

46 ity trial of biannual mass administration of albendazole in a village in Republic of the Congo.

47 Expanded use of albendazole in combination with ivermectin would ensure

48 and tolerability or combined ivermectin and albendazole in Haitian schoolchildren.

49 Women given albendazole in the second trimester of pregnancy had a l

50 Albendazole is a new, broad-spectrum antiparasitic drug,

51 Periodic treatment with albendazole is now used in many school-based intestinal

52 hese nematode species, e.g., the efficacy of albendazole is strong on A. ceylanicum but weak on H. ba

53 Albendazole is the drug of choice against hookworm.

54 lacebo (n=625), 40 mg/kg praziquantel and an albendazole-matching placebo (n=626), or an albendazole-

55 albendazole-matching placebo (n=626), or an albendazole-matching placebo and praziquantel-matching p

56 200-400 micrograms/kg ivermectin and 400 mg albendazole (n = 24).

57 in (mean, 273 micrograms/kg, n = 28), 400 mg albendazole (n = 29), or a combination of 200-400 microg

58 Neither albendazole nor praziquantel treatments affected infant

59 ertical transmission was not associated with albendazole (odds ratio 0.70, 95% CI 0.35-1.42) or prazi

60 Treatment with either albendazole or ivermectin cured all patients with most r

61 All subjects received 4 rounds of albendazole or matching placebo with 3-month intervals,

62 Current MDA approaches using single-dose albendazole or mebendazole are effective for ascariasis,

63 c-worm infections are typically treated with albendazole or mebendazole, but both drugs show low effi

64 nesia and assigned 954 households to receive albendazole or placebo once every 3 mo for 2 y.

65 e-blind study to receive two doses of either albendazole or placebo prior to vaccination and in a gro

66 ceive either 2 sequential doses of 400 mg of albendazole or placebo.

67 difference between the side effect rate from albendazole or the double placebo.

68 among those who received both ivermectin and albendazole (p = 0.0001).

69 greater in the treatment group that received albendazole (P=.06).

70 ning or presumptive treatment with 400 mg of albendazole per day for five days.

71 Albendazole plus diethylcarbamazine significantly reduce

72 Albendazole plus ivermectin significantly reduced preval

73 lumbricoides and investigated the effect of albendazole pretreatment on the postvaccination response

74 were less prevalent among those treated with albendazole (prevalence ratio, 0.60).

75 After implementation of the albendazole protocol, the most common pathogens among 17

76 Treatment with oxantel pamoate-albendazole resulted in higher cure and egg-reduction ra

77 fants of women who had received two doses of albendazole rose by 59 g (95% CI 19-98), and infant mort

78 g treatment with a single dose of ivermectin-albendazole, some of these defects were reversed, with m

79 as significantly higher with oxantel pamoate-albendazole than with mebendazole (31.2% vs. 11.8%, P=0.

80 Presumptive albendazole therapy administered overseas before departu

81 Albendazole therapy was associated with favorable change

82 Following initiation of albendazole therapy, the index patient developed atrial

83 Presumptive administration of albendazole to all immigrants at risk for parasitosis wo

84 International trials have shown albendazole to be safe and effective in eradicating many

85 strategy of biannual mass administration of albendazole to eliminate lymphatic filariasis in areas w

86 es in IFN-gamma were significant only in the albendazole-treated A. lumbricoides infection group (P =

87 ls of IL-2 were significantly greater in the albendazole-treated group compared with the placebo grou

88 ated antigen 4 (CTLA-4) on CD4(+) T cells of albendazole-treated individuals, -0.060 [-0.107 to -0.01

89 After adjustment for sex, age, and region, albendazole-treated refugees were less likely than untre

90 Among 22,586 albendazole-treated refugees, only 4.7% had one or more

91 o effect on infectious disease incidence for albendazole treatment (malaria [hazard ratio 0.95, 95% C

92 Albendazole treatment of individuals with human immunode

93 hes the magnitude of this response, and that albendazole treatment prior to vaccination was able to p

94 infants of mothers with hookworm infection, albendazole treatment reduced interleukin-5 (geometric m

95 Albendazole treatment, compared with placebo, was associ

96 served immediately (within 15 minutes) after albendazole treatment.

97 C recommendation of presumptive predeparture albendazole treatment.

98 were noted between targeted and nontargeted albendazole treatments for the variables measured at eac

99 renatal supplements, in which women received albendazole twice during pregnancy.

100 No serious adverse events associated with albendazole use were reported.

101 Albendazole was administered in all the participants at

102 Albendazole was associated with a significant reduction

103 antimalarials when malaria-positive whereas albendazole was given in a targeted (n = 467; treatment

104 Empiric chemotherapy with albendazole was instituted and surgical en bloc removal

105 emia, combined treatment with ivermectin and albendazole was more effective than treatment with iverm

106 ficacy and safety profile of oxantel pamoate-albendazole when used in the treatment of T. trichiura i

107 include diethylcarbamazine, ivermectin, and albendazole, which are used mostly in combination to red